The best science when not backed by capital, fails to deliver the outcomes needed.
#Europe
#WorldTreatments
#Research
European Economic Area’s share of global clinical trials fell from 18% in 2013 to 9% in 2023, while China’s share rose from under 10% to nearly 30%.
We see the same when it comes to the introduction of new treatments: they reach American patients before Europeans. And even after a medicine is approved in Europe, our fragmented market delivers it slowly and unequally across member states; not all Europeans are equal when it comes to health care. The moral of the story: strong science is not enough. Without capital and scale, Europe risks becoming a market for foreign industries.
Via Euronews: Why Europe struggles to turn world-class science into business
https://www.euronews.com/my-europe/2026/07/07/why-europe-struggles-to-turn-world-class-science-into-business